The fifth meeting of the Hepatitis B and C Network aims to bring together experts from across the EU to discuss how Europe can improve its response to the epidemics of hepatitis B and C with a focus on surveillance, estimating prevalence, and the monitoring of response.
This report outlines suggested steps to develop, implement and coordinate a national STI strategy and action plan. It includes approaches to ensure the necessary stakeholder engagement for such strategies to succeed.
The ECDC Communicable Disease Threats Report (CDTR) is a weekly bulletin for epidemiologists and health professionals on active public health threats. This issue covers the period from 14-24 August 2019 and includes updates on Ebola virus disease in the Democratic Republic of the Congo, monitoring environmental sustainability of Vibrio growth in the Baltic Sea, West Nile virus infection, haemorrhagic fever with renal syndrome in Croatia and Slovenia, the mass gathering of the Hajj in Saudi Arabia and Listeriosis in Spain. (Erratum (26 August 2019): On pages 2 and 5 (West Nile virus infection), the figure of eight deaths in Greece (4), Cyprus (1) and Serbia (1) has been amended to four deaths in Greece (2), Cyprus (1) and Serbia (1)
Targeted testing is an essential element of any strategy to eliminate viral hepatitis across the countries in the European Union and European Economic Area. Some preliminary monitoring results on the response to hepatitis B and C presented around World Hepatitis Day show that diagnosing chronic infections is still a challenge in the EU/EEA.
In 2017, 21 countries reported 4 239 cases of hantavirus infection (0.8 cases per 100 000 population). Two countries, Finland and Germany, accounted for 70.1% of all reported cases. In the absence of a licensed vaccine, prevention mainly relies on rodent control, avoidance of contact and properly cleaning and disinfecting areas contaminated by rodent excreta (urine, saliva or droppings).
This presentation summarises the main data from the ECDC Annual epidemiological reports 2017 on chlamydia, gonorrhoea, lymphogranuloma venereum, (congenital) syphilis
In 2019, the hajj will take place between 9 and 14 August. The risk for EU/EEA citizens to become infected with communicable diseases during the 2019 hajj is considered low, thanks to the vaccination requirements for travelling to Makkah (Mecca) and the Saudi Arabian preparedness plans that address the management of health hazards during and after hajj.